Demand for RNA-based COVID-19 Vaccines Creates Revenue Opportunities for Contact Manufacturers
Epidemiological studies indicate that patients with asthma are not at an increased risk of severe COVID-19. Although the severity of coronavirus in patients with asthma is dependent on many factors, currently, there is scarce information on the risks associated with COVID-19 in patients with severe asthma that consume biologics. Nevertheless, companies in the biologics contract manufacturing market are tapping revenue opportunities in vaccine production in order to reduce incidences of the novel infection.
Companies in the global biologics contract manufacturing market are shifting their focus to RNA-based COVID-19 vaccines. In order to meet the demands of the patients, an increasing number of pharmaceutical and biotech companies are entering into mergers & agreements with contract manufacturers to develop COVID-19 vaccines.
Read Report Overview@ https://www.transparencymarketresearch.com/biologics-contract-manufacturing-market.html
Process Intensification Holds Promising Potentials to Accelerate Business of Life-altering Therapeutics
In order to leverage value-grab opportunities in biologic therapies, it has become imperative to eliminate manufacturing bottlenecks with the help of process intensification (PI). Sartorius AG – an international pharmaceutical and laboratory equipment supplier, covering the segments of bioprocess solutions and lab products & services, is offering solutions for process intensification to accelerate the business of life-altering therapeutics during the ongoing pandemic.
Biologics complexities and long production cycles are fueling the need for PI. Such trends are contributing to the expansion of the biologics contract manufacturing market. PI is helping contract manufacturers to meet key regulatory deadlines, which is crucial for staying ahead in competition. This trend is essential in the manufacturing of biosimilars that need to be produced in several successive batches in a compressed timeline.
Commercialization of Ublituximab for Blood Cancer Treatment
The biologics contract manufacturing market is expected surpass US$ 47.3 Bn by 2031. Monoclonal antibodies are emerging as an important therapeutic approach for blood cancer treatment. TG Therapeutics, Inc. – a clinical-stage biopharmaceutical company, has announced to expand its contract manufacturing deal with Samsung Biologics – a South Korean biotechnology company, to support the production of its investigational anti-CD20 monoclonal antibody, ublituximab.
Get Sample of the Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=78042
Companies in the biologics contract manufacturing market are entering into multiple collaborations to increase the availability of ublituximab and enable its commercialization. Companies are re-evaluating their supply needs and securing long-term capacity to meet the global demand for ublituximab.
Glass Containment Solutions and Drug Delivery Devices Ideal for Next-gen Biologics
The biologics contract manufacturing market is projected to clock a CAGR of 12.2% during the forecast period. Stevanato Group – a specialist in world-class systems, processes, and services for pharmaceutical & healthcare industry, is providing novel glass drug containment solutions and drug delivery devices ideal for next-gen drugs.
Request Report Methodology@ https://www.transparencymarketresearch.com/sample/sample.php?flag=RRM&rep_id=78042
With the help of state-of-the-art analytical services, reliable technology, and manufacturing equipment, companies in the biologics contract manufacturing market are able to capitalize on incremental opportunities. Biotech drugs such as recombinant proteins and monoclonal antibodies are fueling the demand for glass drug containment solutions and drug delivery devices. The high prevalence of rheumatoid arthritis and osteoporosis is triggering the demand for biologics.
Biologics Contract Manufacturing Market: Overview
- According to Transparency Market Research’s latest market report on the global biologics contract manufacturing market for the historical period of 2017–2019 and forecast period from 2021 to 2031, growth of the biopharmaceutical industry and promising drug pipeline are projected to drive the global biologics contract manufacturing market during the forecast period
- According to the report, the global biologics contract manufacturing market was valued at US$ 13.3 Bn in 2020 and is anticipated to expand at a CAGR of 12.2% from 2021 to 2031
Growth of Biopharmaceutical Industry and Promising Drug Pipeline: Key Drivers
- Increase in biopharmaceutical sales and pipeline drugs drive the need of biologics clinical development and manufacturing services, from pre-clinical services to commercial manufacturing
- Over 3,500 recombinant proteins and antibodies are in pre-clinical and clinical trials, including treatments that have been approved
- An increasing number of pipeline molecules are being developed by small and virtual biotech companies. These do not normally have the in-house manufacturing capacity and expertise to bring their candidates to market, and therefore, have a higher propensity to outsource. Presently, these emerging biopharma companies constitute around 80% of the development pipeline.
Increase in Investment in Research & Development
- Demand for the development of newer and technologically enhanced products is rising globally, owing to the treatment efficiency of drugs. Hence, major players operating in the market are investing in research & development programs in order to develop new drugs.
- Recent intensive researches in novel and combination therapies have established the efficacy of biologics for treating a range of chronic diseases such as cancer, rheumatoid arthritis, macular degeneration, and hematological malignancies
- According to CBO, R&D costs have increased by about 8.5% per year in the last decade
- The 2020–2021 coronavirus pandemic has spurred the development of vaccines to halt the spread of COVID-19. In addition to R&D spending by the private sector, the federal government has provided support to the private sector to develop vaccines to address the pandemic.
- Hence, increase in investment in research & development programs is likely to boost the growth of the market during the forecast period
Make an Enquiry Before Buying @ https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=78042
High Cost of Treatment to Restrain Biologics Contract Manufacturing Market
- Biologics are medicines made from living cells that treat common and serious diseases such as cancer, diabetes, rheumatoid arthritis, and other autoimmune diseases. These are highly targeted, efficacious, and have been widely adopted in the treatment of several diseases.
- According to data from the IQVIA Institute, in 2017, biologic drugs represented 2% of all the U.S. prescriptions, but 37% of net drug spending
- Traditional medicines (small molecules) have relatively simple chemical structures. For instance, Lipitor (atorvastatin), a best-selling cholesterol-lowering drug, comprises 76 atoms and is quite cheap to manufacture. However, biologic drugs (or large molecules) such as monoclonal antibodies are complex proteins, manufactured in living cells, which is a costlier process. Humira (adalimumab), the nation’s top drug in terms of revenue, contains 20,067 atoms.
- Therefore, high cost of biologic drugs is likely to restrain the global market during the forecast period
Get Customization Research on this Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=78042
Biologics Contract Manufacturing Market: Competition Landscape
- This report profiles major players in the global biologics contract manufacturing market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments
- The biologics contract manufacturing market is fragmented, with the presence of large number of global players and many small players in regional markets
- Prominent players operating in the global biologics contract manufacturing market include
- Lonza Group
- Samsung Biologics Co., Ltd.
- Patheon by Thermo Fisher Scientific, Inc.
- Cambrex Corporation
- Siegfried Holding AG
- Fujifilm Holding Corporation
- AbbVie, Inc.
- Boehringer Ingelheim
- Recipharm Pharmaceuticals.
- WuXi Biologics
- Catalent, Inc.
About Us
Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. The firm scrutinizes factors shaping the dynamics of demand in various markets. The insights and perspectives on the markets evaluate opportunities in various segments. The opportunities in the segments based on source, application, demographics, sales channel, and end-use are analysed, which will determine growth in the markets over the next decade.
Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision-makers, made possible by experienced teams of Analysts, Researchers, and Consultants. The proprietary data sources and various tools & techniques we use always reflect the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in all of its business reports.
For More Research Insights on Leading Industries, Visit Our YouTube Channel and hit subscribe for Future Update – https://www.youtube.com/channel/UC8e-z-g23-TdDMuODiL8BKQ
Contact
Nikhil Sawlani
Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: 1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com
Blog: https://tmrblog.com
Email: [email protected]